Drug class
Angiotensin Receptor Antagonists clinical trials
A class of medicines: the studies that test any of its 16 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the angiotensin receptor antagonists studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Sacubitril valsartan sodium hydrate
- 88
- Hydrochlorothiazide, losartan drug combination
- 10
- Azilsartan kamedoxomil
- 1
- Azilsartan mepixetil
- 1
Studies by the year they started
1,085 studies that test it; most in 2007 (75); 1 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1991 | 2 |
| 1992 | 1 |
| 1995 | 2 |
| 1997 | 2 |
| 1998 | 10 |
| 1999 | 9 |
| 2000 | 10 |
| 2001 | 14 |
| 2002 | 25 |
| 2003 | 33 |
| 2004 | 59 |
| 2005 | 63 |
| 2006 | 67 |
| 2007 | 75 |
| 2008 | 46 |
| 2009 | 61 |
| 2010 | 36 |
| 2011 | 30 |
| 2012 | 45 |
| 2013 | 41 |
| 2014 | 56 |
| 2015 | 41 |
| 2016 | 38 |
| 2017 | 26 |
| 2018 | 47 |
| 2019 | 34 |
| 2020 | 55 |
| 2021 | 36 |
| 2022 | 30 |
| 2023 | 27 |
| 2024 | 24 |
| 2025 | 17 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Hypertension
- 337
- COVID-19
- 21
Who runs them
Industry 553 · Other 547
Novartis (73) · Boehringer Ingelheim (71) · Novartis Pharmaceuticals (68) · Boryung Pharmaceutical Co., Ltd (39) · Takeda (38) · Sanofi (24) · Chong Kun Dang Pharmaceutical (21) · Daiichi Sankyo (19)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,100
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878Written as Edarbi
- Losartan and Paclitaxel in Platinum Resistant Ovarian CancerNot yet recruitingPhase 2Massachusetts General HospitalNCT07265739Written as losartan
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo CardiomyopathyRecruitingNot applicableUniversity of EdinburghNCT07491718Written as Valsartan
- Intervention for High-normal Blood Pressure in Adults With Type 2 DiabetesRecruitingPhase 4XueQing YuNCT03264352Written as Allisartan Isoproxil
- A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)RecruitingPhase 3Mayo ClinicNCT06150560Written as Losartan
- A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy AdultsNot yet recruitingPhase 1Huons Co., Ltd.NCT07784621Written as Losartan (COZZAR®)
- A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult VolunteersNot yet recruitingPhase 1Huons Co., Ltd.NCT07784608Written as Telmisartan
- Losartan + Sunitinib in Treatment of OsteosarcomaRecruitingPhase 1University of Colorado, DenverNCT03900793Written as Losartan
- Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - PilotRecruitingPhase 2/3Jonathan BeaudoinNCT07539298Written as Valsartan
- Secondhand Tobacco Smoke and Cardiovascular DiseaseRecruitingPhase 4University of California, San FranciscoNCT04715568Written as Losartan
- The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection FractionRecruitingPhase 3John Paul II Hospital, KrakowNCT05508035Written as Sacubitril / Valsartan
- Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated ProteinuriaRecruitingPhase 1Brigham and Women's HospitalNCT07224776Written as sparsentan
- Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)Not yet recruitingPhase 4Seoul National University HospitalNCT07735130Written as Angiotensin Receptor Blocker (ARB)
- Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke SurvivorsRecruitingEarly Phase 1Spaulding Rehabilitation HospitalNCT07588932Written as Telmisartan, Metformin, Cilostazol
- TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin TherapyNot yet recruitingPhase 2Myopharm LimitedNCT07139405Written as Valsartan
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/ValsartanRecruitingPhase 1/2Virginia Commonwealth UniversityNCT05194111Written as Sacubitril-valsartan
- Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary InterventionRecruitingNot applicableNational Medical Research Center for Therapy and Preventive MedicineNCT07683585Written as Losartan + Hydrochlorothiazide
- Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural TanzaniaRecruitingPhase 4Martin RohacekNCT06704633Written as Sacubitril / Valsartan Oral Tablet
- A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A NephropathyRecruitingPhase 2University of LeicesterNCT04663204Written as Sparsentan
- Role of Sympathetic Overactivity and Angiotensin II in PTSD and CVRecruitingPhase 2Emory UniversityNCT02560805Written as Losartan
See all 1,100 studies that test one of the angiotensin receptor antagonists →
Codes
What other systems call Angiotensin Receptor Antagonists · ClinicalTrials.gg INT008922
- MeSH (NLM) D057911Angiotensin Receptor AntagonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D057911 | Angiotensin Receptor Antagonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.